Introduces medical team collaboration through "Operation Robo Angel"... highlights potential to improve access to specialized treatment

Photo courtesy of Xcast

Photo courtesy of Xcast

View original image

XCath Robotics, a company specializing in vascular interventional robotics (hereinafter, X-CAS), announced on October 29, World Stroke Day, that it had released a documentary titled "Operation Robo Angel: Chapter 1," which follows a clinical research project involving remote robotic-assisted medical technology.


The documentary shows how medical teams at a remote location work with local clinicians alongside the patient. It highlights the roles of specialists operating a robot from approximately 200 kilometers away and medical staff supporting the patient on site, while introducing the research process involved in applying new medical technology in real-world clinical settings. Dr. Fred Moll, chairman of X-CAS's board of directors, also appears in the documentary.

X-CAS Releases Documentary on Remote Medical Technology Research for World Stroke Day View original image

The research featured in the documentary was the "Operation Robo Angel" clinical study conducted in Panama in March 2026. Dr. Vitor Mendes Pereira, a neurosurgeon at St. Michael's Hospital in Toronto, Canada, operated the robot from a remote control station installed at Clinica Norte in Santiago, Panama. Using the system, he performed robot-assisted mechanical thrombectomy under the study protocol on a patient with acute ischemic stroke at The Panama Clinic in Panama City, approximately 200 kilometers away.


At the patient's side, a local neurosurgeon and an X-CAS robotic procedure support technician took part. The teams worked together with the remote specialist operating the robot and local medical staff providing support alongside the patient. The documentary focuses on how medical teams in different locations collaborated using remote technology and shares their experiences from the research site.


For stroke, the timing of treatment affects a patient's prognosis. However, access to specialists and treatment facilities varies by region, and patients may not always be able to receive the necessary care in time. This gap in access to medical care is one of the challenges healthcare systems in Korea and around the world must address.


According to a study published in the international journal Circulation in 2023, the median rate of access to mechanical thrombectomy for patients with large-vessel occlusion stroke across the countries and regions studied was 2.79%. X-CAS is researching the potential use of remote robotic technology in addressing access to specialized treatment.


If remote-control technology is commercialized for stroke treatment, where meeting the critical treatment window is essential, it is expected to transform the paradigm of emergency medical care.


X-CAS is headquartered in Houston, United States, and operates a research and development hub in Pangyo, Gyeonggi Province. The company develops robotic systems for vascular interventional procedures. Its system currently under development has not received the medical device approval or certification required for sale in Korea.


"In stroke treatment, the distance between a specialist and a patient can affect treatment time," said Eduardo Fonseca, CEO of X-CAS. "Through this documentary, we wanted to convey the challenges medical professionals face in research on remote robotic-assisted medical technology, as well as the collaboration between medical professionals and researchers that made the work possible."


He added, "Together with researchers in Korea and other countries, we will build clinical evidence and contribute to narrowing regional disparities in access to specialized treatment."


Meanwhile, Model X, which X-CAS is developing separately, received the U.S. Food and Drug Administration's (FDA) Breakthrough Device Designation (BDD) in September 2026 for remote robotic-assisted mechanical thrombectomy in patients with acute ischemic stroke. It was also selected for the FDA's Total Product Life Cycle Advisory Program (TAP).



However, BDD designation and participation in TAP do not constitute FDA marketing authorization. Model X is still in development, and the relevant procedures and product development are ongoing.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing